Compare ATMU & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATMU | IDYA |
|---|---|---|
| Founded | 1958 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 2023 | 2019 |
| Metric | ATMU | IDYA |
|---|---|---|
| Price | $50.56 | $35.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $58.25 | $52.86 |
| AVG Volume (30 Days) | 704.4K | ★ 1.4M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | 12.61 | ★ 61.90 |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $1,764,300,000.00 | $218,710,000.00 |
| Revenue This Year | $15.00 | N/A |
| Revenue Next Year | $5.13 | $201.05 |
| P/E Ratio | $85.73 | ★ N/A |
| Revenue Growth | 5.67 | ★ 3024.43 |
| 52 Week Low | $37.22 | $22.09 |
| 52 Week High | $66.50 | $40.58 |
| Indicator | ATMU | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 52.95 |
| Support Level | $49.65 | $32.85 |
| Resistance Level | $51.16 | $38.17 |
| Average True Range (ATR) | 1.67 | 1.54 |
| MACD | 0.08 | -0.45 |
| Stochastic Oscillator | 46.98 | 16.20 |
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. It designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.